Coneixement de la comunitat

Descobreix Pandipedia

Un directori creixent de respostes útils seleccionades per la comunitat de Pandi. Cerca a la col·lecció o explora els darrers descobriments.

2322 entrades disponibles

Three ethical artificial intelligence metrics managers can track

Transcripció

Here is a quick manager guide to ethical artificial intelligence metrics. For fairness, track false positive and false negative rates by demographic group, then compare the worst and best groups with a gap or ratio. Add bias test coverage across the full lifecycle, including tests that change protected attributes. Tip: review fairness together with accuracy, because one number alone does not tell the whole story. For transparency, measure documentation completeness, traceability, explainability coverage, freshness, and whether users can find clear system descriptions, limits, contact details, and redress paths. Tip: keep records current after each model, data, or policy change. For safety, watch incident rate and severity, adversarial testing coverage, production monitoring coverage, time to detect and repair, and whether corrective actions restore safe function. Tip: set thresholds and limits for each measure in your specific use case, document what you measure and why, and review the scorecard in human and organizational context, not as isolated numbers.

Clinical trials on bioidentical hormones. Query to access registered studies evaluating safety and efficacy.

ClinicalTrials.gov sources for bioidentical hormone studies

I found a small set of directly relevant ClinicalTrials.gov records plus official registry help pages for searching by intervention, condition, recruitment status, or study ID[1][2]. The initial search also surfaced unrelated records, so each registry entry should be confirmed by opening the study page itself[3][4].

ClinicalTrials.gov study records

Direct registry records for the named studies and closely related bioidentical hormone trials. Open each record to verify intervention, status, phase, population, and any posted results.

Official ClinicalTrials.gov search and API guidance

Official help pages for finding studies, using search results, constructing complex queries, checking results, and reading study records, plus the ClinicalTrials.gov FHIR data access page.

Context reviews for safety and efficacy interpretation

Peer-reviewed reviews that help interpret hormone safety and efficacy context, especially compounded bioidentical menopausal hormone therapy and micronized progesterone, but they do not replace individual trial registrations.

TCFD in 2024: broad adoption, thin depth

Five UK infrastructure red flags to check fast

Informe de recerca

ClinicalTrials.gov results: useful evidence or reporting trap?. Synthesize what the results database adds to journal publications, then assess major interpretation risks including self reporting, missing fields, inconsistent entries, imprecise outcome definitions, incomplete participant result reporting, and incomplete registry coverage. Include a compact table separating what reviewers can extract, what they should verify, and what should be treated cautiously.

ClinicalTrials.gov as evidence for semaglutide vs tirzepatide weight loss

ClinicalTrials.gov is best treated as a complement to journal publications, not a replacement. For semaglutide and tirzepatide weight-loss comparisons, it can add protocol-level details and posted summary results, but it does not by itself provide a complete or fully validated comparative evidence base[1][2][3].

The registry is useful because each trial record has a unique NCT identifier, structured registration fields, a History of Changes, and a separate results database that can include participant flow, baseline characteristics, outcome measures, analyses, adverse events, and restrictive agreements. That makes it valuable for checking what was planned versus what was reported, and for spotting missing or shifted outcome information[4][5].

What reviewers can extract, verify, and treat cautiously

This compact view separates the registry value from its main interpretation risks when comparing the two drugs.

What reviewers can extractWhat they should verifyWhat should be treated cautiously
Protocol basics: purpose, recruitment status, design, eligibility criteria, locations, and other registration details[6]Whether the posted record matches the journal paper's final design, population, and endpoint definitions[7][8]Any inference that the registry record alone settles comparative efficacy between semaglutide and tirzepatide[9]
Summary results: participant flow, baseline characteristics, outcome measures, statistical analyses, and adverse events[10]Whether the analysis population is consistent across fields and whether the outcome definition is sufficiently specific[11][12]Imprecise outcome labels or internally inconsistent entries that can blur true between-trial comparability[13][14]
Change history and reporting constraints, including sponsor-investigator agreements that may restrict dissemination[15][16]Whether missing fields are due to nonreporting, delayed updates, or later corrections[17]Assuming the public record is complete, current, or independently verified in all details[18]

Major interpretation risks for this comparison

  • Self-reported data. Results are entered by sponsors or investigators through a web system, so the registry reflects submitted data rather than an independent reanalysis[19].
  • Missing fields. The source explicitly warns that some records lack information, which limits direct comparison and can leave key design or outcome details unresolved[20].
  • Inconsistent entries. Records can contain imprecise or internally inconsistent information, including analysis populations that do not line up cleanly across fields[21][22].
  • Imprecise outcome definitions. A registry outcome label may be too broad for a rigorous semaglutide-versus-tirzepatide comparison unless the protocol or paper clarifies the exact measure and time point[23][24].
  • Incomplete participant-level reporting. The results database is summary-level, not participant-level, so it cannot replace detailed journal reporting or independent data access[25][26].
  • Incomplete registry coverage. Not all trials are registered anywhere, and ClinicalTrials.gov is likely most complete for U.S.-based or multinational drug and device trials, so the registry may miss relevant studies or non-U.S. records[27].

Practical implication: use ClinicalTrials.gov to identify trial existence, planned design, and posted summary results, then verify the final outcome definitions, analysis populations, and any discrepancies against the journal article or other source of record before making comparative claims[28][29].

Bottom line

For semaglutide versus tirzepatide weight-loss evidence, ClinicalTrials.gov adds transparent protocol and summary-results information that journals may not fully expose, but it is not a standalone basis for causal comparison. The safest reading is: extract the registry facts, verify them against publication-level detail, and treat missing, inconsistent, self-reported, or incompletely covered records as evidence gaps rather than as neutral findings[30][31][32][33].

LAUNDRY BEAR’s Zimbra chain, from phish to exfil

Why Miranda Exceptions Still Matter

Transcripció

Miranda exceptions matter because the exclusionary rule does not always erase every piece of evidence tied to an unwarned statement. In practice, tangible evidence like drugs or stolen items may still be usable, and a later properly warned confession may also be admitted. An unwarned statement can sometimes be used to impeach a defendant, and a witness found through that statement may still testify. That is why these exceptions matter operationally: they can preserve key proof for the prosecution and create a real incentive for police to keep seeking evidence even when Miranda warnings are not given. This is only an outline level summary, so anyone briefing a case or making policy decisions should verify the doctrine against primary authority first.

What NIST said was ready now, and what still needs foundational work

This Shrimp Makes a Fake Gunshot

0:00 0:00
Recomanacions

Flowers can bloom inside melting ice.